These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25180131)

  • 21. Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature.
    van Durme C; van Echteld IA; Falzon L; Aletaha D; van der Heijde DM; Landewé RB
    J Rheumatol Suppl; 2014 Sep; 92():9-14. PubMed ID: 25180123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of extracts of leaves from Sparattosperma leucanthum on hyperuricemia and gouty arthritis.
    Lemos Lima Rde C; Ferrari FC; de Souza MR; de Sá Pereira BM; de Paula CA; Saúde-Guimarães DA
    J Ethnopharmacol; 2015 Feb; 161():194-9. PubMed ID: 25500302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    Ito S; Torii T; Nakajima A; Iijima T; Murano H; Horiuchi H; Yamanaka H; Honda M
    BMC Pediatr; 2020 Oct; 20(1):481. PubMed ID: 33059648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of resveratrol on the recurrent attacks of gouty arthritis.
    Chen H; Zheng S; Wang Y; Zhu H; Liu Q; Xue Y; Qiu J; Zou H; Zhu X
    Clin Rheumatol; 2016 May; 35(5):1189-95. PubMed ID: 25451618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents.
    de Souza MR; de Paula CA; Pereira de Resende ML; Grabe-Guimarães A; de Souza Filho JD; Saúde-Guimarães DA
    J Ethnopharmacol; 2012 Aug; 142(3):845-50. PubMed ID: 22732730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hyperuricemia and gout : New aspects of an old disease].
    Witt M; Schulze-Koops H
    Internist (Berl); 2016 Jul; 57(7):656-65. PubMed ID: 27286837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of Treatment in Gouty Arthritis Patients: A Retrospective Study.
    Hanvivadhanakul P; Wongdet R
    J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S46-50. PubMed ID: 26387388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
    Pontremoli R
    Curr Med Res Opin; 2017 Nov; 33(sup3):27-32. PubMed ID: 28952388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gouty arthritis in a 15-year-old girl with Bartter's syndrome.
    Derakhshan N; Derakhshan D; Basiratnia M; Fallahzadeh MH; Hashemi G; Derakhshan A
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1129-31. PubMed ID: 21060187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Hyperuricemia and Gouty Arthritis in BALB/c Mice Using Copper Oxide Nanoparticles.
    Kiyani MM; Rehman H; Hussain MA; Jahan S; Afzal M; Nawaz I; Mahmood T; Bokhari SAI
    Biol Trace Elem Res; 2020 Feb; 193(2):494-501. PubMed ID: 31079329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gout and hyperuricemia.
    Chilappa CS; Aronow WS; Shapiro D; Sperber K; Patel U; Ash JY
    Compr Ther; 2010; 36():3-13. PubMed ID: 21229813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.
    Liu X; Zhai T; Ma R; Luo C; Wang H; Liu L
    Ren Fail; 2018 Nov; 40(1):289-297. PubMed ID: 29619870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can ultrasonography make identification of asymptomatic hyperuricemic individuals at risk for developing gouty arthritis more crystal clear?
    Schlesinger N
    Arthritis Res Ther; 2011 Apr; 13(2):107. PubMed ID: 21542883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis.
    Wang H; Wei Y; Kong X; Xu D
    J Ren Nutr; 2013 Sep; 23(5):389-96. PubMed ID: 23131573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Gout and cardiovascular risk].
    Němec P
    Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the management of gout and hyperuricaemia.
    Hoskison TK; Wortmann RL
    Scand J Rheumatol; 2006; 35(4):251-60. PubMed ID: 16882587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of uric acid metabolism and gouty arthritis in patients with polycystic kidney.
    Hosoya T; Ichida K; Tabe A; Sakai O
    Nihon Jinzo Gakkai Shi; 1993 Jan; 35(1):43-8. PubMed ID: 8336399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice.
    Wang CP; Wang Y; Wang X; Zhang X; Ye JF; Hu LS; Kong LD
    Planta Med; 2011 May; 77(8):786-94. PubMed ID: 21154198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.